Metabolic impact of combined hormonal contraceptives containing estradiol

References

• Hannaford PC, Iversen L, Macfarlane TV, et al. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners’ Oral Contraception Study. BMJ. 2010;340:c927.
   PubMed Web of Science ®Google Scholar
• Dragoman MV. The combined oral contraceptive pill – recent developments, risks and benefits. Best Pract Res Clin Obstet Gynaecol. 2014;28(6):825–834.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Medical eligibility criteria for contraceptive use. 4th ed. Geneva (Switzerland): WHO; 2009.
   Google Scholar
• United Nations Department of Economics and Social Affairs Population Division, World Contraceptive Use. 2009. Available from: www.unpopulation.org.
   Google Scholar
• Grandi G, Cagnacci A, Volpe A. Pharmacokinetic evaluation of desogestrel as a female contraceptive. Expert Opin Drug Metab Toxicol. 2014;10:1–10.
   PubMed Web of Science ®Google Scholar
• Fruzzetti F, Bitzer J. Review of clinical experience with estradiol in combined oral contraceptives. Contraception. 2010;81:8–15.
   PubMed Web of Science ®Google Scholar
• Brennan JJ, Lu Z, Whitman M, et al. Serum concentrations of 17beta-estradiol and estrone after multiple-dose administration of percutaneous estradiol gel in symptomatic menopausal women. Ther Drug Monit. 2001;23:134–138.
   PubMed Web of Science ®Google Scholar
• Lee AJ, Cai MX, Thomas PE, et al. Characterization of the oxidative metabolites of 17β-estradiol and estrone formed by 15 selectively expressed human cytochrome P450 isoforms. Endocrinology. 2003;144:3382–3398.
   PubMed Web of Science ®Google Scholar
• Endrikat J, Parke S, Trummer D, et al. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. Contraception. 2008;78:218–225.
   PubMed Web of Science ®Google Scholar
• Longcope C, Williams KI. The metabolism of estrogens in normal women after pulse injections of 3H-estradiol and 3H-estrone. J Clin Endocrinol Metab. 1974;38:602–607.
   PubMed Web of Science ®Google Scholar
• Ruan X, Seeger H, Mueck AO. The pharmacology of nomegestrol acetate. Maturitas. 2012;71:345–353.
   PubMed Web of Science ®Google Scholar
• Bazin B, Thevenot R, Bursaux C, et al. Effect of nomegestrol acetate, a new 19-nor-progesterone derivative, on pituitary-ovarian function in women. Br J Obstet Gynaecol. 1987;94:1199–1204.
   PubMedGoogle Scholar
• Couzinet B, Young J, Kujas M, et al. The antigonadotropic activity of a 19-nor-progesterone derivative is exerted both at the hypothalamic and pituitary levels in women. J Clin Endocrinol Metab. 1999;84:4191–4196.
   PubMed Web of Science ®Google Scholar
• Grandi G, Mueller M, Bersinger NA, et al. Does dienogest influence the inflammatory response of endometriotic cells? A systematic review. Inflamm Res. 2016;65:183–192.
   PubMed Web of Science ®Google Scholar
• Fraser IS, Römer T, Parke S, et al. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind phase III trial. Hum Reprod. 2011;26:2698–2708.
   Google Scholar
• Grimes DA, Schuly KF, Raymond EG. Surrogate end points in clinical research: hazardous to your health. Obstet Gynecol. 2005;105:1114–1118.
   PubMed Web of Science ®Google Scholar
• Aurell M, Cramér K, Rybo G. Serum lipids and lipoproteins during long-term administration of an oral contraceptive. Lancet. 1966;287:291–293.
   Google Scholar
• Wynn V, Doar JWH, Mills GL. Some effects of oral contraceptives on serum-lipid and lipoprotein levels. Lancet. 1966;288:720–723.
   Google Scholar
• Dhont M. History of oral contraception. Eur J Contracept Reprod Health Care. 2010;15:SS12–S18.
   Web of Science ®Google Scholar
• Fotherby K. Oral contraceptives and lipids. BMJ. 1989;298:1049–1050.
   PubMed Web of Science ®Google Scholar
• Oster P, Arab L, Kohlmeier M, et al. Effects of estrogens and progestogens on lipid metabolism. Am J Obstet Gynecol. 1982;142:773–775.
   PubMed Web of Science ®Google Scholar
• Morin-Papunen L, Martikainen H, McCarthy MI, et al. Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population. Am J Obstet Gynecol. 2008;199:529.e1–529.e10.
   PubMed Web of Science ®Google Scholar
• Endrikat J, Klipping C, Cronin M, et al. An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. Contraception. 2002;65:215–221.
   PubMed Web of Science ®Google Scholar
• van Rooijen M, von Schoultz B, Silveira A, et al. Different effects of oral contraceptives containing levonorgestrel or desogestrel on plasma lipoproteins and coagulation factor VII. Am J Obstet Gynecol. 2002;186:44–48.
   PubMed Web of Science ®Google Scholar
• Wiegratz I, Lee JH, Kutschera E, et al. Effect of dienogest-containing oral contraceptives on lipid metabolism. Contraception. 2002;65:223–229.
   PubMed Web of Science ®Google Scholar
• Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab. 1995;80:1816–1821.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Ferrari S, Tirelli A, et al. Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial. Contraception. 2009;79:111–116.
   PubMed Web of Science ®Google Scholar
• Grandi G, Piacenti I, Volpe A, et al. Modification of body composition and metabolism during oral contraceptives containing non-androgenic progestins in association with estradiol or ethinyl-estradiol. Gynecol Endocrinol. 2014;30:676–680.
   PubMed Web of Science ®Google Scholar
• Grandi G, Napolitano A, Xholli A, et al. Effect of oral contraceptives containing estradiol and nomegestrol acetate or ethinyl-estradiol and chlormadinone acetate on primary dysmenorrhea. Gynecol Endocrinol. 2015;31:774–778.
   PubMed Web of Science ®Google Scholar
• Junge W, Mellinger U, Parke S, et al. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study. Clin Drug Investig. 2011;31:573–584.
   PubMed Web of Science ®Google Scholar
• Ågren UM, Anttila M, Mäenpää-Liukko K, et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. Eur J Contracept Reprod Health Care. 2011;16:444–457.
   PubMed Web of Science ®Google Scholar
• Basdevant A, Pelissier C, Conard J, et al. Effects of nomegestrol acetate (5 mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women. Contraception. 1991;44:599–605.
   PubMed Web of Science ®Google Scholar
• Machado RB, Bernardes CR, de Souza IM, et al. Is lipid profile determination necessary in women wishing to use oral contraceptives? Contraception. 2013;87:801–805.
   PubMed Web of Science ®Google Scholar
• Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev. 2014;4:CD006133.
   PubMed Web of Science ®Google Scholar
• Farley TM, Meirik O, Collins J. Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks. Hum Reprod Update. 1999;5:721–735.
   PubMed Web of Science ®Google Scholar
• Crook D, Godsland I. Safety evaluation of modern oral contraceptives. Effects on lipoprotein and carbohydrate metabolism. Contraception. 1998;57:189–201.
   PubMed Web of Science ®Google Scholar
• Godsland IF, Walton C, Felton C, et al. Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab. 1992;74:64–70.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Paoletti AM, Renzi A, et al. Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. J Clin Endocrinol Metab. 2003;88:3621–3625.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Piacenti I, Zanin R, et al. Influence of an oral contraceptive containing drospirenone on insulin sensitivity of healthy women. Eur J Obstet Gynecol Reprod Biol. 2014;178:48–50.
   PubMed Web of Science ®Google Scholar
• De Leo V, Fruzzetti F, Musacchio MC, et al. Effect of a new oral contraceptive with estradiol valerate/dienogest on carbohydrate metabolism. Contraception. 2013;88:364–368.
   PubMed Web of Science ®Google Scholar
• Yildiz BO. Approach to the patient: contraception in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2015;100:794–802.
   PubMed Web of Science ®Google Scholar
• Weir RJ, Briggs E, Mack A, et al. Blood pressure in women taking oral contraceptives. BMJ. 1974;1(5907):533–535.
   PubMed Web of Science ®Google Scholar
• Wilson ES, Cruickshank J, McMaster M, et al. A prospective controlled study of the effect on blood pressure of contraceptive preparations containing different types and dosages of progestogen. Br J Obstet Gynaecol. 1984;91:1254–1260.
   PubMedGoogle Scholar
• Fuchs N, Dusterberg B, Weber-Diehl F, et al. The effect on blood pressure of a monophasic oral contraceptive containing ethinylestradiol and gestodene. Contraception. 1995;51:335–339.
   PubMed Web of Science ®Google Scholar
• Godsland IF, Crook D, Devenport M, et al. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease. Contraception. 1995;52:143–149.
   PubMed Web of Science ®Google Scholar
• Luque-Ramírez M, Mendieta-Azcona C, Alvarez-Blasco F, et al. Effects of metformin versus ethinylestradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. Fertil Steril. 2009;91:2527–2536.
   PubMed Web of Science ®Google Scholar
• Straznicky NE, Barrington VE, Branley P, et al. A study of the interactive effects of oral contraceptive use and dietary fat intake on blood pressure, cardiovascular reactivity and glucose tolerance in normotensive women. J Hypertens. 1998;16:357–368.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Zanin R, Napolitano A, et al. Modification of 24-h ambulatory blood pressure and heart rate during contraception with the vaginal ring: a prospective study. Contraception. 2013;88:539–543.
   PubMed Web of Science ®Google Scholar
• Lindberg UB, Crona N, Stigendal L, et al. A comparison between effects of estradiol valerate and low dose ethinylestradiol on hemostasis parameters. Thromb Haemost. 1989;6:65–69.
   Google Scholar
• Cagnacci A, Ferrari S, Napolitano A, et al. Combined oral contraceptive containing drospirenone does not modify 24-h ambulatory blood pressure but increases heart rate in healthy young women: prospective study. Contraception. 2013;88:413–417.
   PubMed Web of Science ®Google Scholar
• Grandi G, Xholli A, Napolitano A, et al. Prospective measurement of blood pressure and heart rate over 24 h in women using combined oral contraceptives with estradiol. Contraception. 2014;90:529–534.
   PubMed Web of Science ®Google Scholar
• Conard J, Basdevant A, Thomas JL, et al. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo controlled study with nomegestrol acetate and estradiol. Fertil Steril. 1995;64:957–962.
   PubMed Web of Science ®Google Scholar
• Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five year national case-control study. Contraception. 2002;65:187–196.
   PubMed Web of Science ®Google Scholar
• de Bastos M, Stegeman BH, Rosendal FR, et al. Combined oral contraceptives: venousthrombosis. Cochrane Database Syst Rev. 2014;(3):CD010813..
   PubMed Web of Science ®Google Scholar
• Plu-Bureau G, Maitrot-Mantelet L, Hugon-Rodin J, et al. Hormonal contraceptives and venous thromboembolism: an epidemiological update. Best Pract Res Clin Endocrinol Metabolism. 2013;27:25–34.
   PubMed Web of Science ®Google Scholar
• Commitee for medicinal products for human use (CHMP). Guideline on clinical investigation of steroid contraceptives in women. London: European Medicines Agency. EMEA/CPMP/EWP/519/98 Rev 1; 2005. p. 1–6.
   Google Scholar
• Klipping C, Duijkers I, Parke S, et al. Hemostatic effects of a novel estradiol-based oral contraceptive: an openlabel, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Drugs R D. 2011;11:159–170.
   PubMedGoogle Scholar
• Lete I, Chabbert-Buffet N, Jamin C, et al. Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: a literature review. Eur J Contracept Reprod Health Care. 2015;20:329–343.
   PubMed Web of Science ®Google Scholar
• Raps M, Helmerhorst F, Fleischer K, et al. Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives. J Thromb Haemost. 2012;10:992–997.
   PubMed Web of Science ®Google Scholar
• Gaussem P, Alhenc-Gelas M, Thomas JL, et al. Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17b-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study. Thromb Haemost. 2011;105:560–567.
   PubMed Web of Science ®Google Scholar
• Raps M, Rosendaal F, Ballieux B, et al. Resistance to APC and SHBG levels during use of a four-phasic oral contraceptive containing dienogest and estradiol valerate: a randomized controlled trial. J Thromb Haemost. 2013;11:855–861.
   PubMed Web of Science ®Google Scholar
• Volpe A, Malmusi S, Zanni AL, et al. Oral contraceptives and bone metabolism. Eur J Contracept Reprod H Care. 1997;2:225–228.
   PubMedGoogle Scholar
• Gambacciani M, Spinetti A, Taponeco F, et al. Longitudinal evaluation of perimenopausal vertebral bone loss: effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism. Obstet Gynecol. 1994;83:392–396.
   PubMed Web of Science ®Google Scholar
• Scholes D, Ichikawa L, LaCroix AZ, et al. Oral contraceptive use and bone density in adolescent and young adult women. Contraception. 2010;81:35–40.
   PubMed Web of Science ®Google Scholar
• Nappi C, Bifulco G, Tommaselli GA, et al. Hormonal contraception and bone metabolism: a systematic review. Contraception. 2012;86(6):606–621.
   PubMed Web of Science ®Google Scholar
• Di Carlo C, Gargano V, Sparice S, et al. Short-term effects of an oral contraceptive containing oestradiol valerate and dienogest on bone metabolism and bone mineral density: an observational, preliminary study. Eur J Contracept Reprod Health Care. 2013;18:388–393.
   PubMed Web of Science ®Google Scholar
• Sørdal T, Grob P, Verhoeven C. Effects on bone mineral density of a monophasic combined oral contraceptive containing nomegestrol acetate/17β-estradiol in comparison to levonorgestrel/ethinylestradiol. Acta Obstet Gynecol Scand. 2012;91:1279–1285.
   PubMed Web of Science ®Google Scholar
• Brache V, Payán LJ, Faundes A. Current status of contraceptive vaginal rings. Contraception. 2013;87:264–272.
   PubMed Web of Science ®Google Scholar
• Kumar N, Koide SS, Tsong Y, et al. Nestorone®: a progestin with a unique pharmacological profile. Steroids. 2000;65:629–636.
   PubMed Web of Science ®Google Scholar
• Brache V, Merkatz R, Kumar N, et al. A dose-finding, cross-over study to evaluate the effect of a Nestorone®/Estradiol transdermal gel delivery on ovulation suppression in normal ovulating women. Contraception. 2015;92(4):289–297.
   PubMed Web of Science ®Google Scholar
• Mansour D, Verhoeven C, Sommer W, et al. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur J Contracept Reprod Health Care. 2011;16:430–443.
   PubMed Web of Science ®Google Scholar
• Witjes H, Creinin MD, Sundström-Poromaa I, et al. Comparative analysis of the effects of nomegestrol acetate/17 β-estradiol and drospirenone/ethinylestradiol on premenstrual and menstrual symptoms and dysmenorrhea. Eur J Contracept Reprod Health Care. 2015;20:296–307.
   PubMed Web of Science ®Google Scholar
• Grandi G, Xholli A, Napolitano A, et al. Pelvic pain and quality of life of women with endometriosis during quadriphasic estradiol valerate/dienogest oral contraceptive: a patient-preference prospective 24-week pilot study. Reprod Sci. 2015;22:626–3.
   PubMed Web of Science ®Google Scholar
• Granese R, Perino A, Calagna G, et al. Gonadotrophin-releasing hormone analogue or dienogest plus estradiol valerate to prevent pain recurrence after laparoscopic surgery for endometriosis: a multi-center randomized trial. Acta Obstet Gynecol Scand. 2015;94:637–645.
   Google Scholar